OPTOMED OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.27 EUR | +10.15% |
|
+14.85% | +95.69% |
| May. 07 | Transcript : Optomed Oyj, Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Optomed Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 83.64 | 95.5 | 132.7 | 60.54 | 66.04 | 129.2 | - | - |
| Enterprise Value (EV) 1 | 75.81 | 91.41 | 132.9 | 57.29 | 62.27 | 130.8 | 135.2 | 129.2 |
| P/E ratio | -30.9 x | -30.1 x | -30.6 x | -10.1 x | -13.8 x | -33 x | -45.4 x | 242 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.58 x | 7.34 x | 8.93 x | 4.13 x | 4.37 x | 7.79 x | 4.98 x | 3.93 x |
| EV / Revenue | 5.06 x | 7.03 x | 8.95 x | 3.91 x | 4.12 x | 7.88 x | 5.21 x | 3.93 x |
| EV / EBITDA | -387 x | -125 x | -66.4 x | -29.4 x | -42.4 x | -72.7 x | 48.4 x | 32.3 x |
| EV / FCF | -59.5 x | -29.8 x | -39.1 x | -10.6 x | -75.2 x | -23.8 x | -24.6 x | -323 x |
| FCF Yield | -1.68% | -3.36% | -2.56% | -9.42% | -1.33% | -4.2% | -4.07% | -0.31% |
| Price to Book | 3.69 x | 4.78 x | 7.31 x | - | 3.24 x | 7.9 x | 9.38 x | - |
| Nbr of stocks (in thousands) | 13,192 | 13,227 | 13,539 | 16,167 | 17,776 | 17,776 | - | - |
| Reference price 2 | 6.340 | 7.220 | 9.800 | 3.745 | 3.715 | 7.270 | 7.270 | 7.270 |
| Announcement Date | 2/28/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.98 | 13.01 | 14.85 | 14.66 | 15.1 | 16.6 | 25.95 | 32.9 |
| EBITDA 1 | -0.196 | -0.733 | -2.002 | -1.952 | -1.47 | -1.8 | 2.79 | 4 |
| EBIT 1 | -2.457 | -2.906 | -4.78 | -5.097 | -3.663 | -4.1 | 0.0667 | 1 |
| Operating Margin | -16.41% | -22.33% | -32.19% | -34.77% | -24.26% | -24.7% | 0.26% | 3.04% |
| Earnings before Tax (EBT) 1 | -2.952 | -3.247 | -4.327 | -5.551 | -4.519 | -3.9 | -2.935 | 0.5 |
| Net income 1 | -2.875 | -3.177 | -4.249 | -5.472 | -4.441 | -3.9 | -2.87 | 0.5 |
| Net margin | -19.2% | -24.42% | -28.61% | -37.33% | -29.41% | -23.49% | -11.06% | 1.52% |
| EPS 2 | -0.2053 | -0.2400 | -0.3200 | -0.3700 | -0.2700 | -0.2200 | -0.1600 | 0.0300 |
| Free Cash Flow 1 | -1.274 | -3.069 | -3.402 | -5.399 | -0.828 | -5.5 | -5.5 | -0.4 |
| FCF margin | -8.51% | -23.59% | -22.91% | -36.83% | -5.48% | -33.13% | -21.19% | -1.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.552 | 3.214 | 3.733 | 3.7 | 4.013 | 3.478 | 3.744 | 4.218 | 3.66 | 3.327 | 3.9 | 4.4 | 5 |
| EBITDA 1 | -1.528 | -0.937 | -0.813 | 0.145 | -0.347 | -0.513 | -0.462 | 0.263 | -0.757 | -0.648 | -0.3 | -0.4 | -0.5 |
| EBIT 1 | -2.182 | -1.461 | -1.355 | -1.411 | -0.87 | -1.043 | -1.009 | -0.603 | -1.319 | -1.191 | -0.9 | -1 | -1 |
| Operating Margin | -61.43% | -45.46% | -36.3% | -38.14% | -21.68% | -29.99% | -26.95% | -14.3% | -36.04% | -35.8% | -23.08% | -22.73% | -20% |
| Earnings before Tax (EBT) 1 | -1.956 | -1.39 | - | -1.397 | -1.417 | -1.177 | -1.334 | -0.459 | -1.55 | -1.098 | -0.8 | -1 | -1.1 |
| Net income 1 | -1.936 | -1.37 | - | -1.377 | -1.397 | -1.157 | -1.314 | -0.439 | -1.53 | -1.09 | -0.8 | -1 | -1.1 |
| Net margin | -54.5% | -42.63% | - | -37.22% | -34.81% | -33.27% | -35.1% | -10.41% | -41.8% | -32.76% | -20.51% | -22.73% | -22% |
| EPS 2 | -0.1400 | -0.1000 | -0.1000 | -0.1000 | -0.1000 | -0.0800 | -0.0800 | -0.0300 | -0.0900 | -0.0600 | -0.0400 | -0.0600 | -0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/17/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/17/23 | 5/5/23 | 8/4/23 | 11/3/23 | 2/15/24 | 5/7/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.21 | - | - | 1.6 | 5.93 | - |
| Net Cash position 1 | 7.83 | 4.09 | - | 3.25 | 3.77 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.1064 x | - | - | -0.8889 x | 2.124 x | - |
| Free Cash Flow 1 | -1.27 | -3.07 | -3.4 | -5.4 | -0.83 | -5.5 | -5.5 | -0.4 |
| ROE (net income / shareholders' equity) | -20.4% | -14.9% | -22.9% | -29.3% | -21.8% | -21.3% | -18.8% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.720 | 1.510 | 1.340 | - | 1.150 | 0.9200 | 0.7800 | - |
| Cash Flow per Share 2 | - | - | -0.2200 | -0.1600 | -0.0400 | -0.1300 | -0.1100 | - |
| Capex 1 | 0.26 | 0.27 | 2.57 | 3.03 | 2.41 | 3.1 | 3.6 | 3.5 |
| Capex / Sales | 1.74% | 2.06% | 17.33% | 20.66% | 15.97% | 18.67% | 13.87% | 10.64% |
| Announcement Date | 2/28/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.27
EUR
Average target price
6.633
EUR
Spread / Average Target
-8.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +95.69% | 127M | |
| +7.01% | 215B | |
| +11.01% | 187B | |
| +19.20% | 143B | |
| +30.79% | 110B | |
| +1.48% | 64.68B | |
| +13.95% | 52.96B | |
| -0.16% | 49.84B | |
| -6.20% | 38.32B | |
| +0.91% | 35.86B |
- Stock Market
- Equities
- OPTOMED Stock
- Financials Optomed Oyj
